Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Mycol Med ; 29(3): 233-238, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31204235

ABSTRACT

Non-albicans Candida (NAC) species have emerged as potent pathogenic yeasts among HIV-infected patients. Authors evaluated the epidemiology and antifungal susceptibility testing of non-albicansCandida species colonizing Yaoundé (capital of the Republic of Cameroon, Central Africa) HIV-infected patients. The mucosal specimens were collected and submitted to the mycological diagnosis. Yeast isolates were identified by the Matrix Assisted Laser Desorption Ionisation - Time of Flight Mass Spectrometry (MALDI-TOF MS). The antifungal susceptibility testing was achieved by the CLSI-M27 protocols, and the interpretation of clinical break points (CBPs) and epidemiological cutoff values were in accordance with the CLSI-M60 and M59 recommendations. Four hundred and two patients were recruited and 1218 samples collected. The colonisation frequency was 24.1% and 304 yeasts isolated. Yeast isolates were 113 (37.2%) C. albicans, 2 (0.7%) C. africana and 172 (56.6%) NAC isolates. The NAC isolates were grouped into 13 species including C. krusei (18.1%), C. glabrata (10.9%), C. tropicalis (8.5%) and C. parapsilosis (5.9%) as the major ones. All the isolates appeared to be wild-type for amphotericin B and itraconazole. One (1/33) isolate of C. glabrata was resistant to fluconazole. C. arapsilosis isolates appeared all susceptible to fluconazole. C. tropicalis isolates presented 50% (13/26) resistance to fluconazole. The achieved results bring out new insights about epidemiology of NAC species in Cameroon. The results also highlight the resistance of NAC species to current antifungal drugs.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Drug Resistance, Fungal , HIV Infections/microbiology , Adolescent , Adult , Aged , Cameroon/epidemiology , Candida glabrata/drug effects , Candida tropicalis/drug effects , Female , Fluconazole/pharmacology , HIV Infections/complications , HIV Infections/epidemiology , Humans , Itraconazole/pharmacology , Male , Microbial Sensitivity Tests , Middle Aged , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Young Adult
2.
Ann Trop Med Parasitol ; 104(5): 391-8, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20819307

ABSTRACT

Phytochemical investigation of an ethyl-acetate extract of the stem bark of Markhamia tomentosa (Bignoniaceae), which had good antimalarial activity in vitro, resulted in the isolation of eight known compounds: 2-acetylnaphtho[2,3-b]furan-4,9-dione (1), 2-acetyl-6-methoxynaphtho[2,3-b]furan-4,9-dione (2), oleanolic acid (3), pomolic acid (4), 3-acetylpomolic acid (5), tormentic acid (6), beta-sitosterol (7) and beta-sitosterol-3-O-beta-D-glucopyranoside (8). The structures of these compounds were established by spectroscopic methods. Each of compounds 1, 2, 4 and 5 was evaluated in vitro for its antiprotozoal activities against the ring stages of two chloroquine-resistant strains of Plasmodium falciparum (K1 and W2), the amastigotes of Leishmania donovani, and the bloodstream trypomastigotes of Trypanosoma brucei rhodesiense (the species responsible for human malaria, visceral leishmaniasis and African trypanosomiasis, respectively). Although compounds 1 and 2 exhibited potent antiprotozoal activities, they also showed high toxicity against a mammalian (L-6) cell line.


Subject(s)
Antiprotozoal Agents/pharmacology , Bignoniaceae , Leishmania donovani/drug effects , Plant Extracts/pharmacology , Plasmodium falciparum/drug effects , Trypanosoma brucei rhodesiense/drug effects , Animals , Antiprotozoal Agents/chemistry , Bignoniaceae/chemistry , Cell Line , Cell Survival/drug effects , Parasitic Sensitivity Tests , Plant Extracts/chemistry , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...